Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China.
Department of Orthopedic Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
Biomed Res Int. 2020 May 16;2020:7126982. doi: 10.1155/2020/7126982. eCollection 2020.
To investigate the incidence and risk factors for osteonecrosis of femoral head (ONFH) in multiple myeloma (MM) patients undergoing dexamethasone-based regimens (DBRs).
A retrospective study was conducted in MM patients administered DBRs between December 2012 and April 2015. Demographic, clinical, and laboratory data were extracted to compare between two groups. Incidence of ONFH were calculated and risk factors identified by both univariate and multivariate analysis.
The study group comprised 105 patients undergoing DBRs. Seven patients with ONFH after DBRs were classified as the ONFH group, and the other 98 patients without ONFH were included in the non-ONFH group. Incidence of ONFH was 6.7%. Median age of developing ONFH was 51 years (45-64), and the male to female ratio was 6 : 1. A total of 12 femoral heads were involved, including unilateral in 2 patients and bilateral in 5 patients. After the multivariate analysis, four risk factors were confirmed including male, younger age, cumulative dose of dexamethasone, and hyperlipidemia.
The overall incidence of ONFH in MM patients treated with DBRs is 6.7%, and 4 risk factors are confirmed including male, younger age, cumulative dose of dexamethasone, and hyperlipidemia in our study.
研究接受地塞米松为基础方案（DBR）治疗的多发性骨髓瘤（MM）患者中股骨头坏死（ONFH）的发生率和危险因素。
对 2012 年 12 月至 2015 年 4 月接受 DBR 治疗的 MM 患者进行回顾性研究。提取人口统计学、临床和实验室数据，比较两组间的差异。通过单因素和多因素分析确定 ONFH 的发生率和危险因素。
研究组包括 105 例接受 DBR 治疗的患者。7 例在 DBR 后发生 ONFH 的患者被归类为 ONFH 组，另外 98 例未发生 ONFH 的患者被纳入非 ONFH 组。ONFH 的发生率为 6.7%。发生 ONFH 的中位年龄为 51 岁（45-64 岁），男女比例为 6:1。共有 12 个股骨头受累，其中 2 例为单侧，5 例为双侧。多因素分析后，确认了 4 个危险因素，包括男性、年龄较小、地塞米松累积剂量和高血脂。
在接受 DBR 治疗的 MM 患者中，ONFH 的总体发生率为 6.7%，本研究确定了 4 个危险因素，包括男性、年龄较小、地塞米松累积剂量和高血脂。
